Dr Hannah Gagg

Bsc (Hons), PhD

Clinical Medicine, School of Medicine and Population Health

Postdoctoral Research Associate

h.gagg@sheffield.ac.uk
+44 114 215 9077

Room FU03, F Floor, The Medical School

Full contact details

Dr Hannah Gagg
Clinical Medicine, School of Medicine and Population Health
Room FU03, F Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

I studied biochemistry at Sheffield Hallam University where I was awarded the Biochemical Society Undergraduate Recognition Award for the best overall performance on the BSc biochemistry course, and the Royal Society of Biology Top Student Prize, awarded for the highest final year mark on the BSc biochemistry, human biology or biology courses.

I joined the ex vivo group at the University of Sheffield in 2020 as a PhD student under the supervision of Dr Spencer Collis and Dr Greg Wells. My PhD investigated ex vivo drug screening using human glioblastoma tissue to personalise cancer therapy and replace murine avatars.

I have since continued my research within the ex vivo group as a postdoctoral research associate.

Publications

Journal articles

Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al (2023) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12. View this article in WRRO
Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al () Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12, 954-954.

Conference proceedings papers

Gagg H, Williams S, Rominiyi O, Danson S, Collis S & Wells G (2023) DEVELOPMENT OF GLIEXP; A HIGH-THROUGHPUT EX VIVO DRUG SCREENING PLATFORM FOR GLIOBLASTOMA. Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) F-1286: Ex vivo-led drug discovery in glioblastoma. Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022. View this article in WRRO